INTRANASAL LOWER DOSAGE STRENGTH TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER

1 . A lower dosage strength testosterone gel formulation for nasal administration, said testosterone gel formulation comprising:

a. between about 0.1% to about 1.5% testosterone by weight of said gel formulation; and

b. a pharmaceutically acceptable vehicle.

2 . The testosterone gel formulation of any one of claim 2 , wherein said gel formula further comprises a solvent, a wetting agent, and a viscosity increasing agent.

3 . The testosterone gel formulation of claim 2 , wherein said solvent is castor oil.

4 . The testosterone gel formulation of claim 2 , wherein said wetting agent is an oleoyl polyoxylglyceride.

5 . The testosterone gel formulation of claim 2 , wherein said viscosity increasing agent is colloidal silicon dioxide.

6 . The testosterone gel formulation of any one of claim 1 or 2 , wherein said gel formulation further comprises castor oil, oleoyl polyoxylglycerides and colloidal silicon dioxide.

7 . The testosterone gel formulation of any one of claims 1 - 6 , wherein said gel formulation is a bioequivalent formulation.

8 . The testosterone gel formulation of any one of claims 1 - 6 , wherein said gel formulation is a pharmaceutically equivalent formulation.

9 . The testosterone gel formulation of any one of claims 1 - 6 , wherein said gel formulation is a therapeutically equivalent formulation.

10 . A packaged pharmaceutical comprising:

(a) a lower dosage strength testosterone gel formulation for nasal administration or a pharmaceutically acceptable salt or prodrug thereof, wherein said gel formulation comprises between about 0.1% and 1.5% testosterone by weight; and

(b) associated instructions for using said testosterone gel formulation to treat anorgasmia.

11 . A packaged pharmaceutical comprising:

(a) a lower dosage strength testosterone gel formulation for nasal administration or a pharmaceutically acceptable salt or prodrug thereof, wherein said gel formulation comprises between about 0.1% and 1.5% testosterone by weight; and

(b) associated instructions for using said testosterone gel formulation to treat hypoactive sexual desire disorder (HSDD).

12 . The packaged pharmaceutical of claim 10 or 11 , wherein said testosterone is present as a pharmaceutical composition comprising a therapeutically effective amount of testosterone or a pharmaceutically acceptable salt or prodrug thereof and a pharmaceutically acceptable carrier.

13 . The packaged pharmaceutical of claim 10 or 11 further comprising a step of identifying a subject in need of said pharmaceutical.

14 . A method of treating anorgasmia comprising administering intranasally to a subject said gel formulation of any one of claims 1 - 9 to deliver a therapeutically effective amount of testosterone to effectively treat HSDD.

15 . A method of treating hypoactive sexual desire disorder (HSDD), comprising administering intranasally to each nostril of a subject said gel formulation of any one of claims 1 - 9 to deliver a therapeutically effective amount of testosterone to effectively treat HSDD.

16 . An intranasal method of treating a subject diagnosed with anorgasmia with a lower dosage strength testosterone gel formulation for nasal administration comprising between about 0.1% and 1.5% testosterone by weight of said gel formulation, comprising: applying the testosterone gel formulation into each nostril of said subject at least once a day to deliver an effective amount of testosterone to treat the anorgasmia.

17 . The method of claim 16 , wherein said subject receives said testosterone gel intranasally twice daily.

18 . An intranasal method of treating a subject diagnosed with HSDD with a lower dosage strength testosterone gel formulation for nasal administration comprising between about 0.1% and 1.5% testosterone by weight of said gel formulation, comprising: applying the testosterone gel formulation into each nostril of said subject at least once a day to deliver an effective amount of testosterone to treat the HSDD.

19 . The method of claim 18 , wherein said subject receives said testosterone gel intranasally twice daily.

20 . The method of claim 18 , wherein the lower dosage strength testosterone gel formulation comprises between about 0.24% and 0.72% testosterone by weight of said gel formulation.

21 . The method of claim 18 , wherein the lower dosage strength testosterone gel formulation comprises about 0.24% testosterone by weight of said gel formulation.

22 . The method of claim 18 , wherein the lower dosage strength testosterone gel formulation comprises about 0.48% testosterone by weight of said gel formulation.

23 . The method of claim 18 , wherein the lower dosage strength testosterone gel formulation comprises about 0.72% testosterone by weight of said gel formulation.

24 . A lower dosage strength testosterone gel formulation of claim 1 , wherein the lower dosage strength testosterone gel formulation comprises between about 0.24% and 0.72% testosterone by weight of said gel formulation.

25 . The method of claim 1 , wherein the lower dosage strength testosterone gel formulation comprises about 0.24% testosterone by weight of said gel formulation.

26 . The method of claim 1 , wherein the lower dosage strength testosterone gel formulation comprises about 0.48% testosterone by weight of said gel formulation.

27 . The method of claim 1 , wherein the lower dosage strength testosterone gel formulation comprises about 0.72% testosterone by weight of said gel formulation.

28 . A packaged pharmaceutical of claim 10 , wherein the lower dosage strength testosterone gel formulation comprises between about 0.24% and 0.72% testosterone by weight of said gel formulation.

29 . The method of claim 10 , wherein the lower dosage strength testosterone gel formulation comprises about 0.24% testosterone by weight of said gel formulation.

30 . The method of claim 10 , wherein the lower dosage strength testosterone gel formulation comprises about 0.48% testosterone by weight of said gel formulation.

31 . The method of claim 10 , wherein the lower dosage strength testosterone gel formulation comprises about 0.72% testosterone by weight of said gel formulation.

32 . A packaged pharmaceutical of claim 11 , wherein the lower dosage strength testosterone gel formulation comprises between about 0.24% and 0.72% testosterone by weight of said gel formulation.

33 . The method of claim 11 , wherein the lower dosage strength testosterone gel formulation comprises about 0.24% testosterone by weight of said gel formulation.

34 . The method of claim 11 , wherein the lower dosage strength testosterone gel formulation comprises about 0.48% testosterone by weight of said gel formulation.

35 . The method of claim 11 , wherein the lower dosage strength testosterone gel formulation comprises about 0.72% testosterone by weight of said gel formulation.